NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Co
Go back to NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Co| NAMSCO Corporation (NASDAQ: NAMS) | Delayed: 22.13 -0.36 (1.6%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $22.49 | 52 Week High | $0.00 | |||
| Open | $22.95 | 52 Week Low | $0.00 | |||
| Day High | $23.20 | P/E | N/A | |||
| Day Low | $21.68 | EPS | $0.00 | |||
| Volume | 3,030,490 | |||||
